

# AmeriHealth Caritas Pennsylvania Community Health Choices Specifications for Gaps in Care

## Acute Coronary Syndrome – clopidogrel (Plavix®) Therapy

- **Purpose:** The purpose of this measure is to identify and track members who are diagnosed with acute coronary events and are not filling clopidogrel (Plavix®).

<b>Who is Included?</b> (denominator)	o Members diagnosed with acute coronary syndrome (410.xx or 411.1)
<b>What Pharmacy Claim Data is evaluated?</b> (numerator)	o Claims for clopidogrel  <b>Exclusion:</b> members receiving prasugrel, cilostazol, ticlodipine, dipyridamole, aspirin/dipyridamole, anagrelide
<b>When does the analysis occur?</b>	o Reviews claims from the previous 3 months o Updated Monthly
<b>Where can I get this information?</b>	o Monthly NaviNet report updates reflect Gaps In Care for PCP practice panel membership.  o Quarterly printed reports sent to PCPs reflect Gaps In Care for PCP practice panel membership.  o Panel membership results include indicators for this Gaps In Care measure as “At Risk”
<b>Why does my member have an “At Risk” status?</b>	o Pharmacy claims show a failure to fill clopidogrel in the previous 3 months

**Reference:** Smith SC Jr, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, Grundy SM, Hiratzka L, Jones D, Krumholz HM, Mosca L, Pasternak RC, Pearson T, Pfeffer MA, Taubert KA, AHA/ACC, National Heart, Lung, and Blood Institute. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006 May 16;113(19):2363-72.